Check. Change. Control. Cholesterol™
Recognition Program - Data Collection Worksheet

The following data are needed for each healthcare organization seeking recognition by Check. Change. Control. Cholesterol™. This worksheet can be used to prepare for in advance of registering and/or entering into the data submission platform for award purposes. All award submissions must be entered into our data platform before the close of the recognition cycle. All data is for the calendar year prior to the submission year. For example, all data for 2019 awards is based on patients seen January 1, 2018 through December 31, 2018.

REGISTRATION (required fields)

In addition to basic contact information, the following information is required to register for Check. Change. Control. Cholesterol program. Re-registering year to year is not required.

- What is the total adult (21-75 years) population for the healthcare organization? ________________

- How many of your patients are a race other than white/or identify as Latino or Hispanic ethnicity? ________________

- How many providers are in the health system? (including all Physicians, NP, and PA) ________________

- Are you submitting information for more than one site? If so, how many sites ________________

- Type of Health Care Organization. (FQHC, Primary Care, Department of Health, etc.) ________________

- Published Organization Name (The name of your organization as it should be published for any public recognition materials) ________________
PARTICIPATION AWARD

If requested during registration, registrants will be provided access to our data submission platform. Within the data submission platform, the following questions must be answered in order to be eligible for a Participation Award. Some questions are duplicative from Registration as they can change from year to year.

- **Q1.** What is the total adult (21-75 years) population for the ______________________ healthcare organization?

- **Q2.** How many of your patients are a race other than White and/or identify as Latino or Hispanic ethnicity? ____________

- **Q3.** How many providers are in the health system? ________________
  (including all Physicians, NP, and PA)

- **Q4.** Does your organization currently calculate ASCVD Risk in your EHR? If yes, where?
  - [ ] Yes, My organization currently calculates ASCVD Risk Estimations in our EHR.
  - [ ] Yes, My organization relies on clinicians to calculate ASCVD Risk Estimation external to our EHR (our EHR does not have this functionality).
  - [ ] No, My organization and its providers do not calculate or document ASCVD Risk Estimations at this time.

- **Q5.** Does your organization document the ASCVD Risk score?
  - [ ] Yes. My organization currently collects the results of ASCVD Risk Estimations in a discrete field in our EHR.
  - [ ] Yes, My organization currently collects the results of ASCVD Risk Estimations in a notes field or other non-discrete field in our EHR (there is not a dedicated space in our EHR to capture this information).
  - [ ] No, My organization and its providers do not calculate or document ASCVD Risk Estimations at this time

- **Q6.** My organization is committed to continuously improving use and data capture of ASCVD Risk Estimations into our workflows and EHR systems.
  - [ ] Yes
  - [ ] No
GOLD AWARD: MIPS #438 N/D

To be eligible to receive a Check. Change. Control. Cholesterol Gold Award, organizations will enter their numerator and denominator patient counts for MIPS Measure #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease.

**Denominator:**
How many patients are in these risk groups? (total) **Required Field**

- OR-

Adults aged ≥ 21 years who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD)

- OR-

Adults aged ≥ 21 years who have ever had a fasting or direct low-density lipoprotein cholesterol (LDL-C) level ≥ 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia

- OR-

Adults aged 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL

**Numerator:**
How many of these patients were prescribed or were on statins? **Required Field**
MIPS #438

DESCRIPTION
Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the performance period:

- OR-

- OR-

- OR-

INSTRUCTIONS
This measure is to be submitted once per performance period for patients seen during the performance period. This measure may be submitted by eligible clinicians who provide the services in the measure-specific denominator coding.

DENOMINATOR
The listed denominator criteria is used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions allowed by the measure.

THERE ARE THREE SUBMISSION CRITERIA FOR THIS MEASURE**:

1) Patients aged ≥ 21 years at the beginning of the measurement period with clinical ASCVD diagnosis

   - OR-

2) Patients aged ≥ 21 years at the beginning of the measurement period who have ever had a fasting or direct laboratory result of LDL-C ≥ 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia

   - OR-

3) Patients aged 40 to 75 years at the beginning of the measurement period with Type 1 or Type 2 diabetes and with an LDL-C result of 70–189 mg/dL recorded as the highest fasting or direct laboratory test result in the measurement year or during the two years prior to the beginning of the measurement period

**All patients who meet one or more of the following criteria indicated above would be considered at high risk for cardiovascular events under the ACC/AHA guidelines. When submitting this measure, determine if the patient meets denominator eligibility in order of each risk category.

NUMERATOR
Patients who are actively using or who receive an order (prescription) for statin therapy at any point during the measurement period

DEFINITIONS:
- Statin therapy - Administration of one or more of a group of medications that are used to lower plasma lipoprotein levels in the treatment of hyperlipoproteinemia.